TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Kivo Health raised $10 million in a Series A round led by Allumia Ventures, bringing its total financing to $16 million. The Seattle company says it plans to expand its virtual home-care program nationwide and reach tens of thousands of patients over the next two years; the size and timing of that expansion remain company targets.
Kivo Health, a Seattle-based provider of virtual home care for chronic lung disease, has raised $10 million in Series A financing, according to Home Health Care News. The round brings the company’s total financing to $16 million and is intended to support nationwide expansion of its COPD program.
Allumia Ventures led the round, with additional investment from Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures. The report did not disclose the investors’ individual contributions or other financial terms. Kivo uses technology designed for home use alongside individualized care plans, starting with treatment for chronic obstructive pulmonary disease (COPD).
According to Kivo’s website, enrolled patients receive a home kit containing a tablet, oxygen monitor and exercise bands. They meet virtually with a respiratory therapist to discuss symptoms and establish a plan. The company describes a subsequent nine-week program in which patients meet in small groups with therapists twice a week for breathing instruction, targeted exercises and COPD-management resources.
Kivo co-founder and CEO Victor Sadauskas told Home Health Care News that the company has delivered tens of thousands of sessions and provided access to care for thousands of patients. He said the company plans to reach tens of thousands of patients nationwide over the next two years. Those figures and plans were provided by the company; the report did not provide independent outcome data.
A Push to Scale Home COPD Care
The financing gives Kivo additional capital to pursue geographic expansion of a service intended to help people manage COPD outside traditional in-person appointments. The company’s model relies on remote therapist sessions and equipment used at home, which could extend access for patients who need ongoing support between clinical visits. Whether it improves access or health outcomes at a larger scale will depend on its ability to reach patients and deliver the program consistently.
Kivo says earlier intervention and ongoing coaching can improve quality of life and help avoid hospital stays. It also claims its program reduces total health spending by $8,245 per member per year, citing fewer hospitalizations, emergency-room visits and nursing-home days. The source report does not describe the methodology, comparison group or period behind that estimate, so it should be understood as a company claim rather than an independently verified result.
The company’s stated ambition extends beyond COPD: it intends to adapt its care model for other high-cost chronic illnesses. The funding announcement does not specify which conditions it may target or when those programs might launch.
Products Worth Considering
Blueair Blue Pure 511i Max Air Purifier for Home and Bedroom
BowFlex SelectTech 840 Adjustable Kettlebell
Fitbit Versa 2 Health and Fitness Smartwatch with Bonus Bands
As an affiliate, we earn on qualifying purchases.
How Kivo’s COPD Program Works
Kivo’s program is structured around home-based equipment and recurring virtual contact with respiratory therapists. Based on the company’s description, the therapist first assesses symptoms and creates a personalized plan; participants then attend two virtual group sessions each week for nine weeks. The service combines education and exercise with guidance on managing COPD, rather than relying only on a one-time remote consultation.
The report says Kivo’s program is covered by Medicare, Medicaid and several commercial health plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. Coverage and eligibility can vary by plan and patient, and the report does not provide details about patient costs or enrollment criteria. The new round follows earlier financing that brought Kivo’s total capital raised to $16 million, although the source does not give a breakdown of that earlier funding.
“We have delivered tens of thousands of sessions, providing thousands of patients access to care that improves symptoms and saves health plans money by reducing unnecessary hospitalizations, ER visits and nursing home days.”
— Victor Sadauskas, Kivo Health co-founder and CEO, speaking to Home Health Care News
Expansion Scale and Results Remain Open
The announcement, as reported, does not provide a state-by-state rollout schedule, a breakdown of how the new funding will be spent or a target date for reaching nationwide availability. It is also unclear how many patients are currently enrolled, how many health-plan members are eligible, and how Kivo will measure progress toward its two-year target.
The company’s statements about improved symptoms, avoided care and annual savings are not accompanied in the report by study design, baseline comparisons or independently reviewed results. The $8,245 annual savings estimate therefore cannot be assessed from the available information. Details about expansion into other chronic conditions, including which illnesses and when, were also not disclosed.
Nationwide Rollout Is the Next Test
Kivo says it will use the financing to expand nationwide, with a goal of serving tens of thousands of patients over the next two years. The company has not announced specific launch locations or milestones in the source report. Future updates would clarify where the program becomes available and how quickly it can grow.
Further reporting may also establish whether Kivo publishes independently evaluated results on symptoms, hospital use and spending, and whether it names additional chronic conditions for its care model. For now, the confirmed development is the $10 million financing; the scale, pace and measurable effects of the expansion remain to be established.
Key Questions
How much funding did Kivo Health raise?
Kivo raised $10 million in Series A financing, bringing its reported total financing to $16 million.
Who invested in the Series A round?
Allumia Ventures led the round. Corewell Health Ventures, Y Combinator, Heuristic Capital and MassMutual Ventures also participated, according to Home Health Care News.
What does Kivo Health’s COPD program include?
Kivo describes a home kit with a tablet, oxygen monitor and exercise bands, an initial virtual assessment with a respiratory therapist, and a nine-week course with twice-weekly virtual group sessions.
Does Kivo’s program have health-plan coverage?
The source report says the program is covered by Medicare, Medicaid and several commercial plans, including UnitedHealthcare, Humana, Blue Cross, Aetna and Priority Health. Coverage and eligibility details may differ by plan.
Has Kivo’s claimed annual savings been independently confirmed?
The company claims savings of $8,245 per member per year, but the source report does not provide the methodology or independent validation. The figure should be treated as a company claim.
Source: homehealthcarenews.com
